Oncology Collaboration And Licensing Deals 2021-2026 Benchmark 2,955 Real-World Deals, Financial Terms, Dealmakers And Contracts To Sharpen Partnering Strategy
This report delivers comprehensive intelligence on 2,955 real-world transactions involving oncology assets, technologies and development programs. The report enables pharmaceutical and biotechnology companies to assess oncology partnering trends, benchmark financial terms, identify prospective partners and evaluate comparable transactions.
Designed for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams, the report combines market-wide analysis with detailed deal records and publicly available contract documents. Users can examine who is partnering, which opportunities are attracting investment and how oncology agreements are structured across indications, technologies and stages of development.
Analyze oncology partnering trends
The report assesses oncology dealmaking activity between 2021 and 2026, covering:
- Annual oncology partnering trends Deal activity by transaction type and industry sector Stage of development at signing Technology type and therapeutic modality Cancer indications and therapeutic targets Most active oncology dealmakers Leading transactions by disclosed value Changes in partnering strategies and market priorities
These insights help users determine where deal activity is concentrated and identify the companies, assets, targets and therapeutic areas generating significant partnering interest.
Benchmark oncology deal values and financial terms
Dedicated financial analysis provides real-world benchmarks for evaluating oncology licensing and collaboration opportunities. Available data includes:
- Headline deal values Upfront payments Development, regulatory and commercial milestone payments Royalty rates
Users can review the underlying transactions to interpret disclosed economics in relation to asset maturity, rights granted, geographic scope, technology, competitive environment and transaction structure. This contextual analysis supports opportunity assessment, valuation, internal deal preparation and negotiation.
Identify active oncology companies and prospective partners
Transaction histories reveal organizations with demonstrated interest in specific cancer indications, therapeutic targets, technologies and development stages. The report can support the identification of:
- Companies actively pursuing oncology assets and technologies Potential licensing, research and development partners Organizations repeatedly investing in relevant cancer indications Dealmakers focused on particular modalities or targets Competitors using external innovation to expand oncology portfolios
This evidence-based approach helps companies prioritize prospective partners according to relevant transaction activity rather than broad corporate positioning.
Compare deals by indication, target, technology and development stage
The report allows users to move beyond general oncology benchmarks and investigate transactions aligned with specific strategic requirements. Analysis by therapeutic indication, target, technology and development stage supports more accurate identification of comparable deals and relevant partners.
Evaluate oncology agreement structures
The database includes licensing, collaboration, research, development and related partnering transactions. Subject to available disclosure, deal records may provide information on:
- Rights granted, retained and licensed Research and development responsibilities Exclusivity and geographic scope Intellectual property provisions Development and regulatory obligations Manufacturing and supply responsibilities Commercialization rights Financial consideration, milestones and royalties Governance, term and termination provisions
Where publicly available, underlying contract documents offer additional insight into negotiated language, milestone triggers, royalty provisions, intellectual property management and termination rights. These precedents can support the preparation and negotiation of oncology collaboration and licensing agreements.
Search a comprehensive oncology deal directory
The directory contains 2,955 oncology collaboration and licensing deals searchable by company, technology, indication, target and contract availability. Individual entries connect users with detailed transaction records and associated documentation where available, creating an extensive source of precedent deal intelligence.
Who can benefit from the report?
- Business development and licensing teams: Identify partners, comparable transactions and relevant agreement structures. Search and evaluation teams: Assess companies pursuing opportunities across selected indications, targets, technologies and development stages. Biotechnology companies: Find organizations with demonstrated interest in comparable oncology programs. Corporate and R&D strategy teams: Evaluate competitor portfolios and external innovation strategies. Competitive intelligence teams: Monitor deal activity and changing market priorities. Legal and transaction teams: Review contract precedents and negotiated provisions. Senior management and portfolio strategy teams: Assess where investment and partnering activity are concentrated.
Customized Executive Partnering Briefing
Qualifying customers may also receive a Customized Executive Partnering Briefing that applies the report's intelligence to a specific asset, technology, indication, target or partnering objective. Depending on requirements, the briefing may cover comparable transactions, prospective partners, competitor activity, development-stage analysis, financial and royalty benchmarks, agreement structures and relevant contract insights.
Key Topics Covered
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in oncology dealmaking
2.1. Introduction
2.2. Oncology partnering over the years
2.3. Oncology partnering by deal type
2.4. Oncology partnering by industry sector
2.5. Oncology partnering by stage of development
2.6. Oncology partnering by technology type
2.7. Oncology partnering by therapeutic indication
Chapter 3 - Financial deal terms for oncology partnering
3.1. Introduction
3.2. Disclosed financials terms for oncology partnering
3.3. Oncology partnering headline values
3.4. Oncology deal upfront payments
3.5. Oncology deal milestone payments
3.6. Oncology royalty rates
Chapter 4 - Leading oncology deals and dealmakers
4.1. Introduction
4.2. Most active in oncology partnering
4.3. List of most active dealmakers in oncology
4.4. Top oncology deals by value
Chapter 5 - Oncology contract document directory
5.1. Introduction
5.2. Oncology partnering deals where contract document available
Chapter 6 - Oncology dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by oncology therapeutic target
Deal directory
- Deal directory - Oncology deals by company A-Z Deal directory - Oncology deals by technology type Deal type definitions
Companies Featured
- AbCellera Biologics Adaptimmune Agilent Technologies Akoya Biosciences Alpine Immune Sciences Amgen Arcellx Artiva Biotherapeutics AstraZeneca BeiGene BioNTech Black Diamond Therapeutics Blueprint Medicines Boehringer Ingelheim BridgeBio Pharma Caribou Biosciences Caris Life Sciences Century Therapeutics Charles River Laboratories CRISPR Therapeutics Cullinan Oncology Daiichi Sankyo Dragonfly Therapeutics Eikon Therapeutics ElevateBio Exact Sciences Exelixis Freenome Genentech Genmab Gilead Sciences Guardant Health Illumina Immunocore Innovent Biologics Iovance Biotherapeutics Legend Biotech Moderna Novartis Oxford Nanopore Technologies PathAI Pfizer Regeneron Pharmaceuticals Relay Therapeutics Roche Sanofi Tempus Thermo Fisher Scientific Twist Bioscience Zymeworks
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment